HMGCR and myopathy: However, the administration of these 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (HMGCR; EC 1.1.1.88) [2] may lead to adverse effects such as statin intolerance associated with statin-associated myopathy (SAM) [3].